Total clearance (CL/F) of ribavirin is the factor most influencing incidence of hemolytic anemia in interferon .ALPHA. plus ribavirin combination therapy
- 1 January 2005
- journal article
- Published by Japan Society of Hepatology in Kanzo
- Vol. 46 (3) , 107-118
- https://doi.org/10.2957/kanzo.46.107
Abstract
リバビリン投与時の貧血のリスクの全てを含む因子である全身クリアランス (CL/F) を用いて, リバビリン中止・減量の予見性を検討した. CL/F 15L/hr以下がリバビリン減量・中止に対する最も強い影響因子と同定された. CL/Fを4分位で検討すると, CL/F 15L/hr以下はリバビリン減量のリスク (高齢者, 女性, 低体重, 腎機能低下) であり, リバビリン血中濃度および投与中のヘモグロビン値の低下はCL/Fに依存していた. リバビリンのCL/Fはリバビリン血中濃度の定常期の指標ということから投与4週目のリバビリン濃度と有意に相関していた. CL/Fと4週目のリバビリン実測濃度の相関式から投与4週目のリバビリン濃度を予測すると, 有効性・安全性に関わる重要な濃度として2000-2500ng/ml が想定された. また, バビリン減量のリスク群であるCL/F 15L/hr以下の症例では, 貧血による減量の可能性が投与1週目のヘモグロビン変化量から推定可能と考えられた.This publication has 26 references indexed in Scilit:
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- A 48‐Week Duration of Therapy with Pegylated Interferon α2b plus Ribavirin May Be Too Short to Maximize Long‐Term Response among Patients Infected with Genotype‐1 Hepatitis C VirusThe Journal of Infectious Diseases, 2004
- Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis CJournal of Viral Hepatitis, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001
- Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimenThe Esophagus, 2001
- Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy dataClinical Pharmacology & Therapeutics, 2000
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis CNew England Journal of Medicine, 1998
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusPublished by Elsevier ,1998
- Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α TherapyScience, 1998